Main content area

CXCL10/XCL1 fusokine elicits in vitro and in vivo chemotaxis

Sanchez-Lugo, Yessica E., Perez-Trujillo, Jose J., Gutierrez-Puente, Yolanda, Garcia-Garcia, Aracely, Rodriguez-Rocha, Humberto, Barboza-Quintana, Oralia, Muñoz-Maldonado, Gerardo E., Saucedo-Cardenas, Odila, de Oca-Luna, Roberto Montes, Loera-Arias, Maria J.
Biotechnology letters 2015 v.37 no.4 pp. 779-785
bioactive properties, bioavailability, chemoattractants, chemokine CXCL10, chemotaxis, gene therapy, interleukin-2, lymphocytes, proteins, remission
Fusokines are proteins formed by the fusion of two cytokines. They have greater bioavailability and therapeutic potential than individual cytokines or a combination of different cytokines. Interferon-gamma-inducible protein 10 (CXCL10) and lymphotactin (XCL1) are members of the chemotactic family of cytokines, which induce tumor regression by eliciting immune-system cell chemotaxis. We engineered a replication-deficient adenoviral system expressing CXCL10/XCL1 fusokine (Ad FIL) and assessed its chemotactic response in vitro and in vivo. The CXCL10/XCL1 fusokine elicited a greater chemotactic effect in IL-2 stimulated lymphocytes than individual or combined cytokines in vitro. CXCL10/XCL1 fusokine biological activity was demonstrated in vivo by intratumoral chemoattraction of CXCR3+ cells. Thus, this novel CXCL10/XCL1 fusokine may represent a potential tool for gene therapy treatment of cancer and other illnesses that require triggering immune-system cell recruitment.